Clinical data
ATC code
  • None
  • N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass309.369 g·mol−1
3D model (JSmol)
  • CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3
  • InChI=1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3

Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.


  1. ^ a b Feigin V (June 2002). "Irampanel Boehringer Ingelheim". Curr Opin Investig Drugs. 3 (6): 908–10. PMID 12137411.
  2. ^ Wang KK, Larner SF, Robinson G, Hayes RL (December 2006). "Neuroprotection targets after traumatic brain injury". Curr. Opin. Neurol. 19 (6): 514–9. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687. S2CID 28119069.
  3. ^ Arunabha Ray; Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
  4. ^ Weiser T (April 2005). "AMPA receptor antagonists for the treatment of stroke". Curr Drug Targets CNS Neurol Disord. 4 (2): 153–9. doi:10.2174/1568007053544129. PMID 15857300.